This article was originally published in The Gray Sheet
Executive SummaryPremarket approval application for the Johnson & Johnson subsidiary's Stockert 70 radio frequency generator for cardiac ablation is approved by FDA May 31. Indicated for use "with a Biosense Webster diagnostic/ablation deflectable tip catheter to deliver RF energy during cardiac ablation procedures," the Stockert is the third generator for cardiac ablation to reach the U.S. market, joining Medtronic's Atakr and Boston Scientific's EPT-1000
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.